Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.

Annals of Internal Medicine
Rochelle P WalenskyA David Paltiel

Abstract

Tenofovir alafenamide-emtricitabine (F/TAF) was recently approved as a noninferior and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States. To estimate the greatest possible clinical benefits and economic savings attributable to the improved safety profile of F/TAF and the maximum price payers should be willing to pay for F/TAF over generic F/TDF. Cost-effectiveness analysis. Published literature on F/TDF safety (in persons with and those without HIV) and the cost and quality-of-life effects of fractures and end-stage renal disease (ESRD). Age-stratified U.S. men who have sex with men (MSM) using PrEP. Five years. Health care sector. Preexposure prophylaxis with F/TAF versus F/TDF. Fractures averted, cases of ESRD averted, quality-adjusted life-years (QALYs) saved, costs, incremental cost-effectiveness ratios (ICERs), and maximum justifiable price for F/TAF compared with generic F/TDF. Over a 5-year horizon, compared with F/TDF, F/TAF averted 2101 fractures and 25 cases of ESRD for the 123 610 MSM receiving PrEP, with an ICER of more than $7 million per QALY. At a 50% discount for generic F/TDF ($8300 per year) and a societal willingness t...Continue Reading

References

Aug 26, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Aug 26, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Jun 17, 2003·International Journal of Systematic and Evolutionary Microbiology
Sep 1, 2006·The New England Journal of Medicine·David M CutlerSandeep Vijan
Feb 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A David PaltielRochelle P Walensky
May 15, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Chaitra GopalappaStephanie L Sansom
Jul 23, 2013·Applied Health Economics and Health Policy·Anju ParthanDouglas Taylor
Aug 6, 2014·Clinical Orthopaedics and Related Research·Qian GuJohn Tongue
Nov 17, 2015·Current Opinion in HIV and AIDS·Valentina CambianoAndrew Phillips
Dec 3, 2015·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rabi YacoubChristina M Wyatt
Dec 13, 2017·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·A SvedbomJ A Kanis
Apr 7, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ayami KomatsuShuzo Matsushita
Oct 12, 2019·BMC Infectious Diseases·Bernard SurialUNKNOWN Swiss HIV Cohort Study
Oct 14, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul E SaxJohn R Koethe
Nov 19, 2019·JAMA Internal Medicine·Joshua Khalili, Raphael J Landovitz
Jan 14, 2020·Annals of Internal Medicine·Douglas S KrakowerJulia L Marcus
Mar 9, 2020·The Lancet. HIV·Brooke E Nichols, Stephen M Kissler

❮ Previous
Next ❯

Citations

Mar 10, 2020·Annals of Internal Medicine·Carlos Del Rio, Wendy S Armstrong
Jul 7, 2020·Annals of Internal Medicine·Douglas S KrakowerJulia L Marcus
Mar 25, 2020·Global Public Health·Alisse HannafordSheela V Shenoi
Sep 8, 2020·Annals of Internal Medicine·Kevin L Ard, Rochelle P Walensky

❮ Previous
Next ❯

Software Mentioned

DISCOVER

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.